What is SHUTTLE PHARMACTCLS HLDGS INC's earnings per share (EPS)?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) reported diluted earnings per share of $-7.16 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

SHUTTLE PHARMACTCLS HLDGS INC Financials

SHPH

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows SHUTTLE PHARMACTCLS HLDGS INC (SHPH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SHPH FY2025 2026-05-15

External financing is carrying a cash-burning research business whose liquidity tightened sharply as overhead overtook R&D.

Operating cash burn widened from -$5.6M to -$9.5M over the recent annual periods, and the gap between accounting loss and cash burn stayed fairly narrow, which means the reported losses were translating into real cash use rather than being driven mainly by non-cash items. That matters because financing inflow was $11.0M in the latest year yet year-end cash was only $334K, so new capital was largely replacing cash already spent instead of building a durable reserve.

The cost mix shifted: SG&A reached $5.7M while R&D was $4.1M in the latest year. That suggests a larger share of the cash burn is now tied to corporate and public-company overhead, so the operating loss is no longer just a simple proxy for research activity.

The balance sheet moved from cash-rich after financing to near-term tightness, with cash falling from $8.4M to $334K. Paired with a 0.06x current ratio and 3.6x debt-to-equity, that indicates working-capital pressure and a business model still dependent on repeated external funding rather than internally generated liquidity.

Financial Health Signals

Financial Profile 5/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of SHUTTLE PHARMACTCLS HLDGS INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

SHUTTLE PHARMACTCLS HLDGS INC has elevated debt relative to equity (D/E of 3.65), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 28/100, reflecting increased financial risk.

Liquidity

SHUTTLE PHARMACTCLS HLDGS INC's current ratio of 0.06 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Returns

SHUTTLE PHARMACTCLS HLDGS INC generates a -519.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -1289.5% the prior year.

Piotroski F-Score Weak

2/9

SHUTTLE PHARMACTCLS HLDGS INC passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.81x

For every $1 of reported earnings, SHUTTLE PHARMACTCLS HLDGS INC generates $0.81 in operating cash flow (-$9.5M OCF vs -$11.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$11.6M

YoY-51.2%

SHUTTLE PHARMACTCLS HLDGS INC's EBITDA was -$11.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 51.2% from the prior year.

Net Income

-$11.7M

YoY-28.2%

SHUTTLE PHARMACTCLS HLDGS INC reported -$11.7M in net income in fiscal year 2025. This represents a decrease of 28.2% from the prior year.

EPS (Diluted)

$-7.16

SHUTTLE PHARMACTCLS HLDGS INC earned $-7.16 per diluted share (EPS) in fiscal year 2025. This represents an increase of 91.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$334K

YoY-82.6%

SHUTTLE PHARMACTCLS HLDGS INC held $334K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

SHUTTLE PHARMACTCLS HLDGS INC had 2M shares outstanding in fiscal year 2025. This represents an increase of 1140.8% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-519.9%

YoY+769.6pp

SHUTTLE PHARMACTCLS HLDGS INC's ROE was -519.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 769.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$4.1M

YoY+12.0%

SHUTTLE PHARMACTCLS HLDGS INC invested $4.1M in research and development in fiscal year 2025. This represents an increase of 12.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

SHPH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21
Revenue	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$4.1M+12.0%	$3.6M+2.9%	$3.5M+235.8%	$1.0M+2.5%	$1.0M
SG&A Expenses	$5.7M+307.3%	$1.4M+33.0%	$1.0M+121.0%	$474K+1197.8%	$37K
Operating Income	-$11.9M-54.8%	-$7.7M-30.6%	-$5.9M-151.4%	-$2.3M-34.5%	-$1.7M
Interest Expense	N/A	$100K-95.3%	$2.1M+131.3%	$918K+23796.9%	$4K
Income Tax	N/A	N/A	N/A	N/A	N/A
Net Income	-$11.7M-28.2%	-$9.1M-38.7%	-$6.6M-32.0%	-$5.0M-333.6%	-$1.2M
EPS (Diluted)	$-7.16	$-82.60	$-3.53+30.0%	$-5.04	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$267K	N/A	$943K-8.0%	$1.0M-34.8%	$1.6M	N/A	$1.4M+116.9%	$646K
SG&A Expenses	$1.2M	N/A	$886K-62.2%	$2.3M+293.1%	$597K	N/A	$329K+6.1%	$310K
Operating Income	-$2.2M	N/A	-$2.3M+42.0%	-$3.9M-32.5%	-$3.0M	N/A	-$3.1M-105.8%	-$1.5M
Interest Expense	$9K	N/A	N/A	N/A	N/A	N/A	N/A	$387K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.2M	N/A	-$2.3M+36.7%	-$3.7M-21.4%	-$3.1M	N/A	N/A	-$2.0M
EPS (Diluted)	$-0.43	N/A	$-1.05+68.1%	$-3.29	$-7.60	N/A	$-39.83-65.1%	$-24.12

SHPH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21
Total Assets	$10.5M+318.0%	$2.5M-57.9%	$6.0M-31.2%	$8.7M+1228.0%	$652K
Current Assets	$503K-77.3%	$2.2M-60.5%	$5.6M-34.8%	$8.6M+1583.3%	$510K
Cash & Equivalents	$334K-82.6%	$1.9M-25.5%	$2.6M-69.4%	$8.4M+1567.6%	$505K
Inventory	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.2M+357.5%	$1.8M-5.2%	$1.9M+94.3%	$976K-59.6%	$2.4M
Current Liabilities	$8.0M+419.4%	$1.5M+47.2%	$1.0M+6.8%	$976K-56.0%	$2.2M
Long-Term Debt	N/A	N/A	N/A	N/A	$91K
Total Equity	$2.3M+217.9%	$709K-82.5%	$4.1M-47.2%	$7.7M+535.2%	-$1.8M
Retained Earnings	-$46.3M-33.9%	-$34.6M-36.0%	-$25.4M-35.0%	-$18.8M-36.1%	-$13.8M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$11.8M+12.7%	$10.5M+195.7%	$3.5M-35.6%	$5.5M+3.7%	$5.3M+111.9%	$2.5M+272.1%	$674K-76.1%	$2.8M
Current Assets	$2.5M+389.7%	$503K-84.6%	$3.3M-37.1%	$5.2M+4.7%	$5.0M+124.3%	$2.2M+511.8%	$361K-85.5%	$2.5M
Cash & Equivalents	$1.1M+226.3%	$334K-84.1%	$2.1M-56.5%	$4.8M+6.8%	$4.5M+135.0%	$1.9M+1125.7%	$157K-77.5%	$696K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.5M+2.9%	$8.2M+282.6%	$2.1M+13.2%	$1.9M-6.2%	$2.0M+12.7%	$1.8M-9.6%	$2.0M-1.1%	$2.0M
Current Liabilities	$8.3M+4.3%	$8.0M+305.5%	$2.0M+16.1%	$1.7M-5.0%	$1.8M+16.2%	$1.5M-7.6%	$1.7M+19.8%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.3M+48.4%	$2.3M+61.7%	$1.4M-61.3%	$3.6M+9.7%	$3.3M+363.3%	$709K+153.9%	-$1.3M-264.1%	$801K
Retained Earnings	-$48.5M-4.6%	-$46.3M-6.0%	-$43.7M-5.7%	-$41.3M-9.8%	-$37.6M-8.8%	-$34.6M-4.8%	-$33.0M-13.0%	-$29.2M

SHPH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21
Operating Cash Flow	-$9.5M-29.4%	-$7.3M-31.3%	-$5.6M-109.3%	-$2.7M-787.8%	-$300K
Capital Expenditures	N/A	N/A	$19K	N/A	N/A
Free Cash Flow	N/A	N/A	-$5.6M	N/A	N/A
Investing Cash Flow	-$3.1M-204.8%	$2.9M+203.0%	-$2.8M	N/A	N/A
Financing Cash Flow	$11.0M+191.7%	$3.8M+46.1%	$2.6M-75.7%	$10.6M+1437.8%	$688K
Dividends Paid	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$2.4M-148.4%	-$973K+63.0%	-$2.6M+21.7%	-$3.4M-32.8%	-$2.5M+6.1%	-$2.7M-34.6%	-$2.0M-42.8%	-$1.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$36K	N/A	N/A	N/A	N/A	$0-100.0%	$1.7M+43.1%	$1.2M
Financing Cash Flow	$3.2M+41.4%	$2.3M+2454.4%	-$96K-102.6%	$3.7M-28.5%	$5.1M+14.9%	$4.5M+2363.1%	-$197K+57.4%	-$462K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

SHPH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A
Return on Equity	-519.9%+769.6pp	-1289.5%-1127.0pp	-162.5%-97.5pp	-65.1%	N/A
Return on Assets	-111.9%+253.0pp	-364.9%-254.1pp	-110.8%-53.0pp	-57.7%+119.1pp	-176.8%
Current Ratio	0.06-1.4	1.44-3.9	5.37-3.4	8.79+8.6	0.23
Debt-to-Equity	3.65+1.1	2.53+2.1	0.47+0.3	0.13+0.2	-0.05
FCF Margin	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-64.3%	N/A	-168.4%-65.6pp	-102.8%-9.9pp	-92.9%	N/A	N/A	-253.4%
Return on Assets	-18.2%	N/A	-66.3%+1.1pp	-67.3%-9.9pp	-57.5%	N/A	N/A	-72.2%
Current Ratio	0.30+0.2	0.06-1.6	1.66-1.4	3.07+0.3	2.78+1.3	1.44+1.2	0.22-1.6	1.79
Debt-to-Equity	2.53-1.1	3.65+2.1	1.54+1.0	0.53-0.1	0.62-1.9	2.53+4.0	-1.51-4.0	2.51
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Inmed Pharmaceuticals Inc INM

$5.7M

Redhill Biopharm RDHL

$5.1M

PRF Technologies Ltd. PRFX

$1.3M

Sunshine Biopharma Inc SBFM

$2.4M

Universe Pharmaceuticals Inc UPC

$1.9M

Frequently Asked Questions

Is SHUTTLE PHARMACTCLS HLDGS INC profitable?

No, SHUTTLE PHARMACTCLS HLDGS INC (SHPH) reported a net income of -$11.7M in fiscal year 2025.

What is SHUTTLE PHARMACTCLS HLDGS INC's EBITDA?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) had EBITDA of -$11.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is SHUTTLE PHARMACTCLS HLDGS INC's return on equity (ROE)?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) has a return on equity of -519.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is SHUTTLE PHARMACTCLS HLDGS INC's operating cash flow?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) generated -$9.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are SHUTTLE PHARMACTCLS HLDGS INC's total assets?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) had $10.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does SHUTTLE PHARMACTCLS HLDGS INC spend on research and development?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) invested $4.1M in research and development during fiscal year 2025.

How many shares does SHUTTLE PHARMACTCLS HLDGS INC have outstanding?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) had 2M shares outstanding as of fiscal year 2025.

What is SHUTTLE PHARMACTCLS HLDGS INC's current ratio?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is SHUTTLE PHARMACTCLS HLDGS INC's debt-to-equity ratio?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) had a debt-to-equity ratio of 3.65 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is SHUTTLE PHARMACTCLS HLDGS INC's return on assets (ROA)?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) had a return on assets of -111.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is SHUTTLE PHARMACTCLS HLDGS INC's cash runway?

Based on fiscal year 2025 data, SHUTTLE PHARMACTCLS HLDGS INC (SHPH) had $334K in cash against an annual operating cash burn of $9.5M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is SHUTTLE PHARMACTCLS HLDGS INC's Piotroski F-Score?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are SHUTTLE PHARMACTCLS HLDGS INC's earnings high quality?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is SHUTTLE PHARMACTCLS HLDGS INC?

SHUTTLE PHARMACTCLS HLDGS INC (SHPH) scores 5 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.